295 related articles for article (PubMed ID: 33042110)
1. G-CSF and G-CSFR Modulate CD4 and CD8 T Cell Responses to Promote Colon Tumor Growth and Are Potential Therapeutic Targets.
Karagiannidis I; Jerman SJ; Jacenik D; Phinney BB; Yao R; Prossnitz ER; Beswick EJ
Front Immunol; 2020; 11():1885. PubMed ID: 33042110
[TBL] [Abstract][Full Text] [Related]
2. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
[TBL] [Abstract][Full Text] [Related]
3. [Expression of granulocyte colony-stimulating factor receptor in colitis-associated colonic carcinogenesis].
Wang W; Yuan W; Wei XD; Qi J; Ma J
Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):653-658. PubMed ID: 30293388
[No Abstract] [Full Text] [Related]
4. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
5. G-CSF and G-CSFR Induce a Pro-Tumorigenic Macrophage Phenotype to Promote Colon and Pancreas Tumor Growth.
Karagiannidis I; de Santana Van Vilet E; Said Abu Egal E; Phinney B; Jacenik D; Prossnitz ER; Beswick EJ
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33036138
[TBL] [Abstract][Full Text] [Related]
6. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
[TBL] [Abstract][Full Text] [Related]
7. G-CSF Is a Novel Mediator of T-Cell Suppression and an Immunotherapeutic Target for Women with Colon Cancer.
Ray AL; Saunders AS; Nofchissey RA; Reidy MA; Kamal M; Lerner MR; Fung KM; Lang ML; Hanson JA; Guo S; Urdaneta-Perez MG; Lewis SE; Cloyde M; Morris KT
Clin Cancer Res; 2023 Jun; 29(11):2158-2169. PubMed ID: 36951682
[TBL] [Abstract][Full Text] [Related]
8. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.
Jarnicki AG; Lysaght J; Todryk S; Mills KH
J Immunol; 2006 Jul; 177(2):896-904. PubMed ID: 16818744
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells.
Chakraborty A; Guha S
Urology; 2007 Jun; 69(6):1210-5. PubMed ID: 17572226
[TBL] [Abstract][Full Text] [Related]
10. A novel co-culture assay to assess anti-tumor CD8
Olivo Pimentel V; Yaromina A; Marcus D; Dubois LJ; Lambin P
J Immunol Methods; 2020 Dec; 487():112899. PubMed ID: 33068606
[TBL] [Abstract][Full Text] [Related]
11. MondoA-Thioredoxin-Interacting Protein Axis Maintains Regulatory T-Cell Identity and Function in Colorectal Cancer Microenvironment.
Lu Y; Li Y; Liu Q; Tian N; Du P; Zhu F; Han Y; Liu X; Liu X; Peng X; Wang X; Wu Y; Tong L; Li Y; Zhu Y; Wu L; Zhang P; Xu Y; Chen H; Li B; Tong X
Gastroenterology; 2021 Aug; 161(2):575-591.e16. PubMed ID: 33901495
[TBL] [Abstract][Full Text] [Related]
12. Targeting
Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
Front Immunol; 2021; 12():738958. PubMed ID: 34721405
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
14. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589
[TBL] [Abstract][Full Text] [Related]
15. T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice.
Liu W; Guo W; Shen L; Chen Z; Luo Q; Luo X; Feng G; Shu Y; Gu Y; Xu Q; Sun Y
Oncotarget; 2017 Jan; 8(5):7586-7597. PubMed ID: 27935860
[TBL] [Abstract][Full Text] [Related]
16. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
[TBL] [Abstract][Full Text] [Related]
17. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
Stoppacciaro A; Forni G; Colombo MP
Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363
[TBL] [Abstract][Full Text] [Related]
18. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma.
Stoppacciaro A; Melani C; Parenza M; Mastracchio A; Bassi C; Baroni C; Parmiani G; Colombo MP
J Exp Med; 1993 Jul; 178(1):151-61. PubMed ID: 7686211
[TBL] [Abstract][Full Text] [Related]
19. Highly Expressed Granulocyte Colony-Stimulating Factor (G-CSF) and Granulocyte Colony-Stimulating Factor Receptor (G-CSFR) in Human Gastric Cancer Leads to Poor Survival.
Fan Z; Li Y; Zhao Q; Fan L; Tan B; Zuo J; Hua K; Ji Q
Med Sci Monit; 2018 Mar; 24():1701-1711. PubMed ID: 29567938
[TBL] [Abstract][Full Text] [Related]
20. Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor.
Zilocchi C; Stoppacciaro A; Chiodoni C; Parenza M; Terrazzini N; Colombo MP
J Exp Med; 1998 Jul; 188(1):133-43. PubMed ID: 9653090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
